Holen Sie sich die Stockscreener-App
0.5931
0.42%
0.0025
Nexgel Inc Aktie (NXGL) Neueste Nachrichten
NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal - MyChesCo
NexGel Inc Warrant (NXGLW) - Minichart
NexGel Appoints Ian Blackman as New Chief Financial Officer - The Globe and Mail
NexGel, Inc. 2025 SEC Filing – Executive Compensation, Corporate Governance, Ownership & Audit Disclosure - Minichart
Board pay, ownership and new CFO terms at NexGel (NASDAQ: NXGL) - Stock Titan
NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal - Stock Titan
Maxim Group Maintains NexGel(NXGL.US) With Buy Rating, Maintains Target Price $2 - Moomoo
NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical - MyChesCo
Asymmetry Point LP (NXGL) files Schedule 13G/A showing 8.8% ownership - Stock Titan
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Langhorne’s Nexgel Transforms Near Disaster into ‘Three-Team Trade’ Acquisition - BUCKSCO.Today
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Investing News Network
Nexgel, Inc. Appoints Ian Blackman as Chief Financial Officer - marketscreener.com
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue - The Business Journals
NexGel receives Nasdaq notice for minimum bid price deficiency By Investing.com - Investing.com India
NEXGEL, INC. Receives Nasdaq Delisting Notice for Failure to Meet Minimum Bid Price Requirement - Minichart
NexGel receives Nasdaq notice for minimum bid price deficiency - Investing.com
NexGel Receives Nasdaq Deficiency Notice Over Bid Price - TipRanks
NexGel Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
NexGel (NASDAQ: NXGL) warned by Nasdaq over sub-$1 share price and delisting risk - Stock Titan
NXGL (NexGel Inc) shares fall over 15 percent after Q4 2025 EPS loss lands far below analyst consensus estimates.Fast Rising Picks - Xã Thanh Hà
NexGel Bets Big With Transformational Acquisition And Financing - The Globe and Mail
NEXGEL Reschedules Shareholder Call, Revises Celularity Financing - MyChesCo
NEXGEL closes Celularity biomaterials deal, raises $5.5 million By Investing.com - Investing.com India
Celularity Announces Closing of Transaction with NexGel - Investing News Network
NXGL: Acquisition triples revenue and accelerates profitability, transforming the business platform - TradingView
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
Nexgel IncCo to Pay Celularity $13.3 Mln I - Moomoo
NEXGEL Secures Strategic Financing and Regenerative Portfolio License - TipRanks
NexGel Closes Celularity Biomaterials License Terms and Secures $6.9M Convertible Note Financing - TradingView
NEXGEL (NASDAQ: NXGL) triples revenue outlook with Celularity deal, $6.9M notes - Stock Titan
Celularity Inc. announced that it has received $13.3 million in funding from NEXGEL, Inc. - marketscreener.com
NexGel closes acquisition of products from Celularity - TipRanks
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Investing News Network
Nexgel new strategic partner, Sequence LifeScience, leads financing with $5.5 million to complete acquisition of Celularity degenerative disease segment - marketscreener.com
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy - TipRanks
NEXGEL closes Celularity biomaterials deal, raises $5.5 million - Investing.com
Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™ - Bitget
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - The Manila Times
Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms - Stock Titan
Celularity Closes Transaction with NexGel to Monetize Biomaterials - Intellectia AI
Celularity sells biomaterials assets, cuts nearly $13M of debt - Stock Titan
NexGel Inc stock (US65340W1027): Is its hydrogel tech edge strong enough for medtech growth? - AD HOC NEWS
NEXGEL, Inc. completed the acquisition of Portfolio of Commercial-stage Regenerative Biomaterial Products of Celularity Inc. for 15.8 million. - marketscreener.com
NEXGEL reschedules shareholder call, revises financing plan - MSN
NexGel Inc stock (US65340W1027): Why its hydrogel tech edge matter more now for specialized medical - AD HOC NEWS
NEXGEL (NXGL) price target decreased by 66.67% to 2.04 - MSN
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET - The Manila Times
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
2.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):